Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PRNP | P04156 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | TYMS | P04818 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL845638 | 0.86 | ALDH1A1 (0.44) | ALDH1A1MAPTSMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL845526 | 0.78 | ALDH1A1 (0.47) | ALDH1A1MAPTSMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL857677 | 0.74 | TYMS (0.53) | ALDH1A1MAPTSMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL860937 | 0.74 | TYMS (0.50) | ALDH1A1MAPTSMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL28702281 | 0.73 | ALDH1A1 (0.63) | ALDH1A1MAPTSMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL847350 | 0.72 | PRNP (0.51) | ALDH1A1MAPTSMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL862262 | 0.70 | PRNP (0.52) | ALDH1A1MAPTSMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL2997807 | 0.70 | SMN1; SMN2 (0.63) | ALDH1A1MAPTSMN1; SMN2HPGDL3MBTL1 | |
| SCHEMBL859927 | 0.68 | KMT2A (0.55) | ALDH1A1MAPTHPGDL3MBTL1KDM4E | |
| SCHEMBL2129231 | 0.68 | CDC25B (0.62) | ALDH1A1MAPTHPGDL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122780-A1 | Compounds, Compositions and Methods for Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122780-A1 | Compounds, Compositions and Methods for Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122780-A1 | Compounds, Compositions and Methods for Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2432774-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS | Ardea Biosciences, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010135530-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135530-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122780-A1 | Compounds, Compositions and Methods for Modulating Uric Acid Levels | XDH, PON1, RBP4 | ALDH1A1 188/4885MAPT 3061/4885SMN1; SMN2 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.